Literature DB >> 9876114

Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.

M Renatus1, W Bode, R Huber, J Stürzebecher, M T Stubbs.   

Abstract

The trypsin-like serine proteinase superfamily contains a number of potential therapeutic targets, many of which are unsuitable for routine X-ray crystallographic studies. We have cocrystallized a selection of benzamidine-based inhibitors with bovine trypsin and solved their structures to a resolution of up to 1.7 A. Despite similar chemical formulas, the inhibitors exhibit a range of diverse binding modes that reflect their inhibitory spectra against the serine proteinases trypsin, thrombin, factor Xa, tissue-type plasminogen activator (tPA) and urokinase (uPA). In contrast to the compact folded conformations of thrombin inhibitors which allow optimal binding in the well-defined hydrophobic S2/S4 pocket of thrombin, those effective against factor Xa exhibit an extended conformation that allows occupation of the S3/S4 region, where hydrophobic and electrostatic interactions can stabilize the conformation. One group of inhibitors containing an N-terminal 2,4, 6-triisopropylphenylsulfonyl (TIPPS) moiety show little or no penetration into the S3/S4 subsites of trypsin. These latter sites are occluded in uPA, explaining why this class of compounds is effective against uPA. Despite presenting an extensive hydrophobic surface toward the solvent, the Ki values for TIPPS-containing compounds against trypsin is in the range 10(-7) to 10(-8) M. Comparison of the binding of a bis-benzamidine inhibitor in trypsin and tPA indicate that a shift in potency can be induced by relatively minor changes in binding mode. Implications for the inhibition of these proteinases are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9876114     DOI: 10.1021/jm981068g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation.

Authors:  Manel G Medina; Maria Dolores Ledesma; Jorge E Domínguez; Miguel Medina; Delia Zafra; Francesc Alameda; Carlos G Dotti; Pilar Navarro
Journal:  EMBO J       Date:  2005-04-21       Impact factor: 11.598

2.  Design of a high fragment efficiency library by molecular graph theory.

Authors:  Jennifer Venhorst; Sara Núñez; Chris G Kruse
Journal:  ACS Med Chem Lett       Date:  2010-09-03       Impact factor: 4.345

3.  Role of residue Y99 in tissue plasminogen activator.

Authors:  A Vindigni; M Winfield; Y M Ayala; E Di Cera
Journal:  Protein Sci       Date:  2000-03       Impact factor: 6.725

4.  Rotational-echo double-resonance NMR-restrained model of the ternary complex of 5-enolpyruvylshikimate-3-phosphate synthase.

Authors:  Lynda M McDowell; Barbara Poliks; Daniel R Studelska; Robert D O'Connor; Denise D Beusen; Jacob Schaefer
Journal:  J Biomol NMR       Date:  2004-01       Impact factor: 2.835

Review 5.  A method to study the expression of DNA methyltransferases in aging systems in vitro.

Authors:  Joel B Berletch; Sharla M O Phipps; Sabrina L Walthall; Lucy G Andrews; Trygve O Tollefsbol
Journal:  Methods Mol Biol       Date:  2007

6.  Development of a Mammalian suspension culture for expression of active recombinant human urokinase-type plasminogen activator.

Authors:  Erica Atkins; Stephanie Zamora; Britny J Candia; Amy Baca; Robert A Orlando
Journal:  Cytotechnology       Date:  2005-09       Impact factor: 2.058

7.  The plasminogen activator system modulates sympathetic nerve function.

Authors:  Ulrich Schaefer; Takuji Machida; Sandra Vorlova; Sidney Strickland; Roberto Levi
Journal:  J Exp Med       Date:  2006-08-28       Impact factor: 14.307

8.  Selenourea: a convenient phasing vehicle for macromolecular X-ray crystal structures.

Authors:  Zhipu Luo
Journal:  Sci Rep       Date:  2016-11-14       Impact factor: 4.379

9.  Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator.

Authors:  Justin J Heynekamp; Lucy A Hunsaker; Thomas A Vander Jagt; Lorraine M Deck; David L Vander Jagt
Journal:  BMC Chem Biol       Date:  2006-02-08

10.  Drug screening boosted by hyperpolarized long-lived states in NMR.

Authors:  Roberto Buratto; Aurélien Bornet; Jonas Milani; Daniele Mammoli; Basile Vuichoud; Nicola Salvi; Maninder Singh; Aurélien Laguerre; Solène Passemard; Sandrine Gerber-Lemaire; Sami Jannin; Geoffrey Bodenhausen
Journal:  ChemMedChem       Date:  2014-09-04       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.